Wires

Eli Lilly to target cancer drug developers for deals

Oct 23 (Reuters) - Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

"Probably because of the number of opportunities, you will see us active in oncology - that's where a lot of early stage biotech is," Ricks said. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)